ES2185817T3 - Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato. - Google Patents
Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato.Info
- Publication number
- ES2185817T3 ES2185817T3 ES96944726T ES96944726T ES2185817T3 ES 2185817 T3 ES2185817 T3 ES 2185817T3 ES 96944726 T ES96944726 T ES 96944726T ES 96944726 T ES96944726 T ES 96944726T ES 2185817 T3 ES2185817 T3 ES 2185817T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- protons
- alginate
- anticide
- pumps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
FORMA FARMACEUTICA DE DOSIFICACION ORAL QUE CONTIENE UN INHIBIDOR DE LA BOMBA DE PROTONES SENSIBLE AL ACIDO Y UNO O MAS AGENTES ANTIACIDOS O UN ALGINATO EN FORMULACION FIJA, EN LA QUE EL INHIBIDOR DE LA BOMBA DE PROTONES ESTA PROTEGIDO POR UNA CUBIERTA ENTERICA Y UNA CAPA OPCIONAL DE SEPARACION ENTRE EL INHIBIDOR DE LA BOMBA DE PROTONES Y LA CUBIERTA ENTERICA. LA FORMULACION FIJA ADOPTA LA FORMA DE COMPRIMIDOS MULTICAPA, SOBRES O TABLETAS EN MULTIPLES UNIDADES. LA FORMA DE DOSIFICACION EN UNIDADES MULTIPLES ES LA PREFERIDA. LA NUEVA FORMULACION FIJA RESULTA ESPECIALMENTE UTIL EN EL TRATAMIENTO DE LOS TRASTORNOS ASOCIADOS CON LA DISPEPSIA, COMO LA PIROSIS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9600071A SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | New oral formulation of two active ingredients I |
SE9600071 | 1996-01-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2185817T3 true ES2185817T3 (es) | 2003-05-01 |
ES2185817T5 ES2185817T5 (es) | 2009-11-24 |
Family
ID=20400969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96944726T Expired - Lifetime ES2185817T5 (es) | 1996-01-08 | 1996-12-20 | Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato. |
Country Status (35)
Country | Link |
---|---|
US (1) | US6183776B1 (es) |
EP (1) | EP0813424B2 (es) |
JP (1) | JPH11501950A (es) |
KR (1) | KR100490075B1 (es) |
CN (1) | CN1080125C (es) |
AR (1) | AR005281A1 (es) |
AT (1) | ATE228009T1 (es) |
AU (1) | AU712669B2 (es) |
BR (1) | BR9607350B1 (es) |
CA (1) | CA2213996C (es) |
CZ (1) | CZ293583B6 (es) |
DE (1) | DE69624907T3 (es) |
DK (1) | DK0813424T4 (es) |
EE (1) | EE04002B1 (es) |
EG (1) | EG23821A (es) |
ES (1) | ES2185817T5 (es) |
HK (2) | HK1001763A1 (es) |
HU (1) | HU229153B1 (es) |
IL (1) | IL121651A (es) |
IS (1) | IS2716B (es) |
MX (1) | MX9706785A (es) |
MY (1) | MY116091A (es) |
NO (1) | NO326656B1 (es) |
NZ (1) | NZ325977A (es) |
PL (1) | PL187075B1 (es) |
PT (1) | PT813424E (es) |
RU (1) | RU2179453C2 (es) |
SA (1) | SA97170553B1 (es) |
SE (1) | SE9600071D0 (es) |
SK (1) | SK283695B6 (es) |
TR (1) | TR199700916T1 (es) |
TW (1) | TW464514B (es) |
UA (1) | UA45392C2 (es) |
WO (1) | WO1997025066A1 (es) |
ZA (1) | ZA9610935B (es) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US8071128B2 (en) * | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
WO1998023272A1 (en) * | 1996-11-27 | 1998-06-04 | The Procter & Gamble Company | Compositions and methods for the treatment of gastrointestinal disorders |
MX9703918A (es) * | 1997-05-28 | 1998-11-30 | J Marshall M D Barry | Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior. |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
WO1999010000A1 (en) * | 1997-08-25 | 1999-03-04 | The Procter & Gamble Company | Combined preparations for treating upper gastrointestinal tract distress |
WO1999029299A1 (en) * | 1997-12-08 | 1999-06-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel suppository form comprising an acid-labile active compound |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
FR2774906B1 (fr) * | 1998-02-13 | 2000-05-12 | Rhodia Chimie Sa | Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation |
EP1121103B1 (en) * | 1998-05-18 | 2006-12-20 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets comprising a benzimidazole |
UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
DK1561458T3 (da) | 1998-07-28 | 2010-10-25 | Takeda Pharmaceutical | Hurtigt henfaldende fast middel |
SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
MXPA01009934A (es) * | 1999-03-29 | 2002-06-21 | American Home Prod | Sistema de recubrimiento. |
WO2001003707A1 (en) * | 1999-07-12 | 2001-01-18 | Smithkline Beecham Corporation | Heartburn treatment |
CA2387746C (en) | 1999-10-20 | 2010-06-29 | Koji Ukai | Methods for stabilizing benzimidazole-based compounds |
US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
KR20040018463A (ko) * | 2001-07-16 | 2004-03-03 | 아스트라제네카 아베 | 양성자 펌프 억제제 및 제산제를 함유하는 제약 제제 |
AR036354A1 (es) * | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
US20040213848A1 (en) * | 2001-09-28 | 2004-10-28 | Shun-Por Li | Modified release dosage forms |
US9358214B2 (en) * | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US7008777B2 (en) | 2001-10-15 | 2006-03-07 | Barry J. Marshall | System for the detection of urease and method for using same |
JP2005521662A (ja) * | 2002-01-25 | 2005-07-21 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤の経粘膜送達 |
KR100479637B1 (ko) * | 2002-02-01 | 2005-03-31 | 한국화학연구원 | 란소프라졸을 함유하는 경구제제 및 그의 제조방법 |
CO5400144A1 (es) * | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
MXPA04009968A (es) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20040081700A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Dose titratable liquid dosage forms of acid labile drugs |
US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
US6663892B1 (en) * | 2002-08-19 | 2003-12-16 | L. Perrigo Company | Multiple portion tablet |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
EP2596792A1 (en) * | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004066924A2 (en) * | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
US7258981B2 (en) * | 2003-01-24 | 2007-08-21 | Clontech Laboratories, Inc. | Sensitive proteasome sensor constructs and methods for their design and use |
JP2006518751A (ja) * | 2003-02-20 | 2006-08-17 | サンタラス インコーポレイティッド | 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物 |
EP1759692A3 (en) * | 2003-03-10 | 2007-09-12 | Novartis AG | Taste-masked solid veterinary compositions |
KR101173580B1 (ko) * | 2003-03-18 | 2012-08-13 | 코와 가부시키가이샤 | 제산제 조성물 |
EP2112920B1 (en) | 2003-06-26 | 2018-07-25 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
WO2005011637A1 (ja) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | 用時分散型製剤 |
US7282050B2 (en) * | 2003-10-31 | 2007-10-16 | Medtronic, Inc. | Ablation of exterior of stomach to treat obesity |
US7252665B2 (en) * | 2003-10-31 | 2007-08-07 | Medtronic, Inc | Ablation of stomach lining to reduce stomach acid secretion |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
US7041124B2 (en) * | 2003-12-23 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | System and method for providing therapy to a portion of a body |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2005123042A1 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release pharmaceutical formulation |
US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
GB2418854B (en) * | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2584957C (en) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
SE530605C2 (sv) * | 2005-09-29 | 2008-07-15 | Barbara Nelson | Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CN101389316A (zh) * | 2005-12-28 | 2009-03-18 | 武田药品工业株式会社 | 控制释放固体制剂 |
CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
WO2007122478A2 (en) * | 2006-04-20 | 2007-11-01 | Themis Laboratories Private Limited | Multiple unit compositions |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2007138606A2 (en) * | 2006-06-01 | 2007-12-06 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
AR056062A1 (es) | 2006-06-05 | 2007-09-19 | Bago Sa Labor | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
CN101120930B (zh) * | 2006-08-11 | 2010-09-29 | 石药集团中奇制药技术(石家庄)有限公司 | 一种奥美拉唑组合物及其制备方法 |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
EP2086543A2 (en) | 2006-10-27 | 2009-08-12 | The Curators of the University of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
CN101259140B (zh) * | 2007-03-08 | 2012-08-22 | 重庆北碚现代应用药物研究所 | 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法 |
ES2759626T3 (es) * | 2007-05-07 | 2020-05-11 | Evonik Operations Gmbh | Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco |
EP2044929A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Oral fast distintegrating tablets |
ITFI20070253A1 (it) * | 2007-11-09 | 2009-05-10 | Valpharma Internat S P A | Formulazioni farmaceutiche per la somministrazione di ipp. |
JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
EP2127643A1 (de) * | 2008-05-30 | 2009-12-02 | Bayer Schering Pharma Aktiengesellschaft | Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe |
KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
WO2010038241A2 (en) * | 2008-09-30 | 2010-04-08 | Panacea Biotec Limited | Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid |
JP2012072061A (ja) * | 2009-01-29 | 2012-04-12 | Eisai R & D Management Co Ltd | 新規組成物 |
CA2766524A1 (en) * | 2009-06-25 | 2010-12-29 | Pozen Inc. | Method for treating a patient in need of aspirin therapy |
AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
SG10201407965XA (en) | 2009-12-02 | 2015-02-27 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
US20120294937A1 (en) | 2009-12-29 | 2012-11-22 | Novartis Ag | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
TW201127375A (en) * | 2010-01-08 | 2011-08-16 | Eurand Inc | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
BR112012026860A2 (pt) | 2010-04-23 | 2018-06-05 | S Biotek Holding Aps | composição farmacêutica sólida para neutralizar ácido estomacal |
EP2797600A4 (en) | 2011-12-28 | 2015-09-16 | Pozen Inc | IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID |
US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
US20150238514A1 (en) * | 2014-02-21 | 2015-08-27 | William Armstrong | Protective Supplement Configuration |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
AU2016404808A1 (en) * | 2016-04-29 | 2018-12-13 | Alan Thompson | Veterinary composition |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TR201723199A2 (tr) * | 2017-12-30 | 2019-07-22 | Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi | Yeni farmasötik bileşimler. |
KR102006777B1 (ko) * | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
KR102080023B1 (ko) * | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
JP2021533177A (ja) * | 2018-08-23 | 2021-12-02 | チョン クン ダン ファーマシューティカル コーポレイション | エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤 |
MX2022004464A (es) * | 2019-10-17 | 2022-05-03 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de la bomba de protones y un antiacido. |
MX2022009121A (es) * | 2020-01-23 | 2022-08-18 | Hanmi Pharm Ind Co Ltd | Formulacion farmaceutica compuesta que comprende un inhibidor de la bomba de protones y un antiacido. |
EP4070789A4 (en) * | 2020-01-23 | 2024-01-24 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITE FORMULATION WITH PROTON PUMP INHIBITOR AND ANTACID |
KR102608889B1 (ko) * | 2020-07-14 | 2023-12-04 | 한미약품 주식회사 | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 |
KR20220065997A (ko) * | 2020-11-13 | 2022-05-23 | (주)휴온스 | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
CN114569579B (zh) | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
KR20230097346A (ko) * | 2021-12-24 | 2023-07-03 | 한미약품 주식회사 | 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제 |
KR102553713B1 (ko) * | 2022-11-18 | 2023-07-10 | 고덕상 | 미네랄 촉매제를 이용한 양식어류사료 제조방법 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
JPS5598120A (en) | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
US4340582A (en) | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
JPS5973529A (ja) | 1982-10-12 | 1984-04-25 | Sankyo Co Ltd | 被覆固形製剤の製造法 |
US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
GB2132887A (en) | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
JPH0759499B2 (ja) | 1984-02-10 | 1995-06-28 | ベンツォン ファーマ エイ/エス | 拡散被覆された複合単位服用剤 |
US4568560A (en) | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
SE450087B (sv) | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
EP0250572A1 (en) | 1986-01-03 | 1988-01-07 | The University Of Melbourne | Gastro-oesophageal reflux composition |
US5112813A (en) | 1986-03-07 | 1992-05-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Process for the preparation of a viscosity-stable antacid composition |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
DK179687D0 (da) | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
KR960011236B1 (ko) † | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | 제약학적 조성물 및 고체 제형 |
EP0294933B1 (en) † | 1987-05-08 | 1992-03-11 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions |
GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
BE1002406A5 (fr) | 1988-09-20 | 1991-01-29 | Glaxo Group Ltd | Compositions pharmaceutiques. |
SE8803822D0 (sv) * | 1988-10-26 | 1988-10-26 | Novel dosage form | |
US5026559A (en) † | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
DE4023028A1 (de) * | 1990-07-20 | 1992-01-23 | Hoechst Ag | Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen |
US5244670A (en) * | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
JP3142919B2 (ja) | 1991-11-06 | 2001-03-07 | 旭化成株式会社 | セルロース誘導体ラテックス及びその製法 |
US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
US5229137A (en) † | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
US5447918A (en) | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
JPH07509702A (ja) | 1992-08-05 | 1995-10-26 | エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド | ペレット薬剤組成物 |
US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
CA2110313C (en) † | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
WO1995001795A1 (en) | 1993-07-06 | 1995-01-19 | Merck & Co., Inc. | H2 antagonist-alginate-antacid combinations |
AU7218294A (en) † | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-alginate combinations |
WO1995008332A1 (en) | 1993-09-20 | 1995-03-30 | The Procter & Gamble Company | Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection |
JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
US5798120A (en) † | 1993-10-12 | 1998-08-25 | Tokyo Tanabe Company Limited | Enteric granule-containing tablets |
GB2285989A (en) | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
AUPM596894A0 (en) | 1994-05-30 | 1994-06-23 | Hybrid Scientific Pty Ltd | Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders |
MX9600857A (es) | 1994-07-08 | 1997-06-28 | Astra Ab | Forma de dosificacion i en tabletas, con unidades multiples. |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
AUPM695294A0 (en) | 1994-07-20 | 1994-08-11 | Borody, Thomas Julius | Improved combination therapy dose unit |
EP0814773B1 (en) | 1995-03-17 | 2001-07-25 | The Boots Company PLC | Pectin liquid pharmaceutical compositions |
US5824339A (en) † | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
WO1998023272A1 (en) | 1996-11-27 | 1998-06-04 | The Procter & Gamble Company | Compositions and methods for the treatment of gastrointestinal disorders |
-
1996
- 1996-01-08 SE SE9600071A patent/SE9600071D0/xx unknown
- 1996-12-20 AU AU13241/97A patent/AU712669B2/en not_active Ceased
- 1996-12-20 NZ NZ325977A patent/NZ325977A/xx not_active IP Right Cessation
- 1996-12-20 DK DK96944726T patent/DK0813424T4/da active
- 1996-12-20 DE DE69624907T patent/DE69624907T3/de not_active Expired - Lifetime
- 1996-12-20 IL IL12165196A patent/IL121651A/xx not_active IP Right Cessation
- 1996-12-20 UA UA97104949A patent/UA45392C2/uk unknown
- 1996-12-20 EP EP96944726A patent/EP0813424B2/en not_active Expired - Lifetime
- 1996-12-20 CA CA002213996A patent/CA2213996C/en not_active Expired - Fee Related
- 1996-12-20 US US08/750,934 patent/US6183776B1/en not_active Expired - Lifetime
- 1996-12-20 PL PL96322175A patent/PL187075B1/pl not_active IP Right Cessation
- 1996-12-20 TR TR97/00916T patent/TR199700916T1/xx unknown
- 1996-12-20 HU HU9904024A patent/HU229153B1/hu not_active IP Right Cessation
- 1996-12-20 PT PT96944726T patent/PT813424E/pt unknown
- 1996-12-20 MX MX9706785A patent/MX9706785A/es not_active IP Right Cessation
- 1996-12-20 JP JP9525131A patent/JPH11501950A/ja active Pending
- 1996-12-20 WO PCT/SE1996/001737 patent/WO1997025066A1/en active IP Right Grant
- 1996-12-20 ES ES96944726T patent/ES2185817T5/es not_active Expired - Lifetime
- 1996-12-20 CN CN96193594A patent/CN1080125C/zh not_active Expired - Fee Related
- 1996-12-20 SK SK1169-97A patent/SK283695B6/sk not_active IP Right Cessation
- 1996-12-20 KR KR1019970706236A patent/KR100490075B1/ko not_active IP Right Cessation
- 1996-12-20 EE EE9700192A patent/EE04002B1/xx not_active IP Right Cessation
- 1996-12-20 AT AT96944726T patent/ATE228009T1/de active
- 1996-12-20 BR BRPI9607350-0A patent/BR9607350B1/pt not_active IP Right Cessation
- 1996-12-20 CZ CZ19972747A patent/CZ293583B6/cs not_active IP Right Cessation
- 1996-12-20 RU RU97116726/14A patent/RU2179453C2/ru not_active IP Right Cessation
- 1996-12-26 AR ARP960105899A patent/AR005281A1/es not_active Application Discontinuation
- 1996-12-27 TW TW085116139A patent/TW464514B/zh not_active IP Right Cessation
- 1996-12-30 ZA ZA9610935A patent/ZA9610935B/xx unknown
-
1997
- 1997-01-07 MY MYPI97000065A patent/MY116091A/en unknown
- 1997-01-07 EG EG1897A patent/EG23821A/xx active
- 1997-01-15 SA SA97170553A patent/SA97170553B1/ar unknown
- 1997-08-20 IS IS4548A patent/IS2716B/is unknown
- 1997-09-04 NO NO19974071A patent/NO326656B1/no not_active IP Right Cessation
-
1998
- 1998-02-05 HK HK98100847A patent/HK1001763A1/xx not_active IP Right Cessation
- 1998-11-06 HK HK98111792A patent/HK1017992A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2185817T3 (es) | Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato. | |
ES2185816T3 (es) | Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico. | |
ES2176436T3 (es) | Nueva forma de dosificacion farmaceutica oral. | |
AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
ES2035064T5 (es) | Aposito para heridas. | |
ES2082288T3 (es) | Composiciones terapeuticas para administracion intranasal de ketorolaco. | |
AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
ECSP003836A (es) | Composicion estable para dosis oral de liberacion extendida | |
AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
BR0215404A (pt) | processo e dispositivo para reduzir dosagem terapêutica | |
UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
IT1316777B1 (it) | Nebulizzatore medico per liquido da utilizzare nella terapiarespiratoria e altre applicazioni | |
AR015933A1 (es) | Esmalte para unas con actividad antipsoriasica y procedimiento para su preparacion | |
PT879056E (pt) | Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados | |
CY1109726T1 (el) | Δισκιο εγχρωμου πυρηνα | |
BRPI0311511A8 (pt) | "preparações farmacêuticas líquidas, e sua aplicação". | |
AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
AR005860A1 (es) | Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización. | |
ES2188995T3 (es) | Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales. | |
ES2152272T3 (es) | Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
ES2144017T3 (es) | Composicion para el tratamiento externo de la piel. | |
AR015956A1 (es) | Composiciones de citoquinas oromucosales y usos de las mismas | |
ES2137267T3 (es) | Comprimidos dispersables en agua. |